CELL INTELLIGENCE · 肿瘤细胞治疗研究

elranatamab 与医生选择治疗方案（非 BCMA 靶向方案）用于日本三类暴露多发性骨髓瘤患者的成本效果分析

Cost-effectiveness analysis of elranatamab versus physician's choice of treatment (non-BCMA-directed regimens) in patients with triple class exposed m

从医疗支付方角度来看，在基础案例和情景分析中，elranatamab 相较于 PCT 具有成本效益，其 ICER 始终低于日本通常接受的阈值；但鉴于非锚定 MAIC 和长期外推的不确定性，应谨慎解读这一结果。

AML/MDS 细胞治疗的最新进展

Recent advances in cell therapy for AML/MDS.

抗 B 细胞成熟抗原 CAR-T 治疗后原有结节病发作：模拟髓外骨髓瘤复发的皮肤病变

Flare of Pre-Existing Sarcoidosis After Anti-B-Cell Maturation Antigen CAR-T Therapy: Cutaneous Lesions Mimicking Extramedullary Myeloma Relapse.

迟发性帕金森综合征可能相关于 elranatamab 治疗复发/难治性多发性骨髓瘤：一例特征不明确的神经系统事件病例报告

Delayed-onset parkinsonism possibly associated with elranatamab treatment for relapsed/refractory multiple myeloma: a case report of a poorly characte

日本 CAR-T 细胞产品的现状和问题：监管视角

Current status and issues with CAR-T cell products in Japan: a regulatory perspective.

含环磷酰胺强化多药桥接治疗对多发性骨髓瘤 idecabtagene vicleucel 治疗后结局的影响

Impact of Intensive Cyclophosphamide-Containing Multi-Agent Bridging Therapy on Outcomes after Idecabtagene Vicleucel in Multiple Myeloma.

CAR-T 细胞疗法治疗多发性骨髓瘤的疗效决定因素与优化：现状与未来展望

Determinants of Efficacy and Optimization of Chimeric Antigen Receptor T-Cell Therapy for Treating Multiple Myeloma: Current Status and Future Perspec

病例报告：自体干细胞输注使 BCMA 靶向双特异性抗体治疗所致多发性骨髓瘤严重血细胞减少后造血功能得以恢复

Case Report: autologous stem cell boost enables hematopoietic recovery after severe cytopenia induced by BCMA-targeted bispecific antibody therapy in

多发性骨髓瘤中三种 BCMA 靶向治疗的特征与应用

Characteristics and utilization of the three BCMA-targeted therapies in multiple myeloma.

多发性骨髓瘤 CAR-T 与双特异性抗体治疗的进展与未来展望

Advances and future perspectives in chimeric antigen receptor T-cell and bispecific antibody therapies for multiple myeloma.